Market Performance - U.S. stocks showed mixed performance with the Dow Jones index falling over 200 points, down 0.60% to 49,293.33, while the NASDAQ gained 0.17% to 23,773.29 and the S&P 500 dropped 0.08% to 6,971.95 [1] - In the energy sector, shares increased by 1.4%, while financial stocks decreased by 1.8% [1] Inflation Data - Inflation remained steady in December, with the Consumer Price Index rising 2.7% year over year, matching economist expectations and unchanged from November [2] - Monthly consumer prices increased by 0.3%, also in line with forecasts [2] Commodity Prices - Oil prices rose by 2.6% to $61.06, while gold increased by 0.1% to $4,620.80 [4] - Silver prices surged by 4.4% to $88.860, whereas copper fell by 0.1% to $6.0295 [4] European Market Trends - European shares were mixed, with the eurozone's STOXX 600 falling 0.08% and Spain's IBEX 35 Index rising 0.08% [5] - London's FTSE 100 slipped 0.03%, Germany's DAX gained 0.06%, and France's CAC 40 fell 0.14% [5] Asian Market Performance - Asian markets closed mixed, with Japan's Nikkei surging 3.10% and Hong Kong's Hang Seng Index gaining 0.90% [8] - Conversely, China's Shanghai Composite fell 0.64% and India's BSE Sensex decreased by 0.30% [8] Company-Specific Movements - Beyond Air Inc shares surged 172% to $2.39 following an acquisition agreement, potentially receiving up to $32.5 million [7] - Ambitions Enterprise Management Co LLC shares increased by 106% to $10.90 due to a year-over-year EPS increase [7] - TryHard Holdings Ltd shares rose by 77% to $40.96 after announcing a collaboration agreement and a $10 million share repurchase program [7] - Signing Day Sports Inc shares dropped 57% to $0.25 after announcing a public offering [7] - Travere Therapeutics Inc shares fell 32% to $23.16 following preliminary fourth-quarter financial results [7] - Wealthfront Corp shares decreased by 18% to $10.34 due to weak quarterly sales [7]

Market Overview - U.S. stocks traded lower, with the Dow Jones index falling more than 300 points, down 0.66% to 49,264.22, NASDAQ down 0.15% to 23,699.14, and S&P 500 down 0.24% to 6,960.41 [1] - Financial stocks dipped by 1.7% on Tuesday [2] - Energy shares gained by 1.4% [1] Company Earnings - JPMorgan Chase & Co reported better-than-expected earnings for Q4, with earnings of $5.23 per share, surpassing the analyst consensus estimate of $4.92 per share. Quarterly sales were $46.767 billion, exceeding the consensus estimate of $46.024 billion [3] Commodity Market - Oil traded up 2% to $60.69, while gold traded down 0.5% at $4,592.90. Silver rose 0.7% to $85.700, and copper increased by 0.4% to $6.0545 [5] International Markets - European shares were mostly lower, with the eurozone's STOXX 600 down 0.1%, Spain's IBEX 35 down 0.2%, London's FTSE 100 down 0.1%, Germany's DAX down 0.1%, and France's CAC 40 down 0.4% [6] - Asian markets closed mixed, with Japan's Nikkei up 3.10%, Hong Kong's Hang Seng Index up 0.90%, while China's Shanghai Composite fell 0.64% and India's BSE Sensex fell 0.30% [7] Stock Movements - Beyond Air Inc shares surged 153% to $2.22 after XTL Biopharmaceuticals agreed to acquire an 85% stake in its NeuroNOS subsidiary, with potential payments up to $32.5 million [9] - Ambitions Enterprise Management Co LLC shares increased by 105% to $10.80 following a year-over-year increase in H1 EPS results [9] - AlphaTON Capital Corp shares rose 81% to $1.65 [9] - Signing Day Sports Inc shares dropped 55% to $0.26 after announcing a $5.6 million public offering [9] - Rich Sparkle Holdings Ltd shares fell 27% to $68.16, and Mingteng International Corp Inc shares decreased by 29% to $0.054 [9] Economic Indicators - The NFIB Small Business Optimism Index surged to 99.5 in December, marking its highest level since August [8] - The annual inflation rate remained at 2.7% in December, unchanged from the previous month [10]

Core Insights - XTL Biopharmaceuticals Ltd. has announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc., which focuses on disease-modifying therapeutics for Autism Spectrum Disorder (ASD) and neuro-oncology [1][2] - The acquisition positions XTL as a significant player in the autism therapeutics market, addressing a critical unmet medical need as 1 in 31 U.S. children are affected by autism, with no FDA-approved disease-modifying therapies currently available [3][4] Company Overview - NeuroNOS was founded by Professor Haitham Amal, a leading autism researcher, and has strengthened its scientific leadership by adding two Nobel Laureates in Chemistry, enhancing its potential for therapeutic innovation [5][7] - The company’s drug development platform targets the underlying molecular mechanisms of autism through a proprietary family of small molecules that can cross the blood-brain barrier [8] Market Opportunity - The autism crisis has led to increased strain on healthcare systems and families, with a significant rise in cases prompting urgent calls for new therapeutic pathways and research funding from U.S. policymakers [3][4] - The U.S. government has allocated $50 million in new NIH funding for autism research initiatives, indicating a shift in regulatory priorities towards autism treatment development [4] Transaction Details - XTL will acquire 85% of NeuroNOS for a combination of cash, shares, and milestone payments totaling up to $32.5 million, with the transaction subject to shareholder approval [10][11] - The milestone payments include up to $5.5 million for clinical development and up to $26 million for achieving product sales targets [11] Scientific Validation - NeuroNOS has secured FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma, which provide market exclusivity and expedited regulatory review upon approval [9] - Preclinical studies have shown that the platform addresses core pathological mechanisms in autism, validating nitric oxide dysregulation as a therapeutic target [8]

Core Insights - XTL Biopharmaceuticals Ltd. has announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc., which focuses on disease-modifying therapeutics for Autism Spectrum Disorder (ASD) and neuro-oncology [1][2] - The acquisition positions XTL as a significant player in the autism therapeutics market, addressing a critical unmet medical need as 1 in 31 U.S. children are affected by autism, with no FDA-approved disease-modifying therapies currently available [3][4] Company Overview - NeuroNOS was founded by Professor Haitham Amal, a leading autism researcher, and has strengthened its scientific leadership by adding two Nobel Laureates in Chemistry, enhancing its potential for therapeutic innovation [5][7] - The company’s drug development platform targets the underlying molecular mechanisms of autism through a proprietary family of small molecules that can cross the blood-brain barrier [8] Market Opportunity - The autism crisis has led to increased strain on healthcare systems and families, with a significant rise in cases prompting urgent calls for new therapeutic pathways and research funding from U.S. policymakers [3][4] - The U.S. government has allocated $50 million in new NIH funding for autism research initiatives, indicating a shift in regulatory priorities towards autism treatment development [4] FDA Designations and Financial Terms - NeuroNOS has secured FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma, which provide market exclusivity and expedited regulatory review [9] - The transaction terms include XTL acquiring 85% of NeuroNOS for 19.9% of XTL's issued share capital, $1 million in cash, and milestone payments up to $32.5 million [10][11] Strategic Commitment - Both XTL and Beyond Air are committed to advancing NeuroNOS's autism treatment programs with urgency, aiming to bring innovative therapies to market [11][12] - The acquisition is seen as a pivotal moment for NeuroNOS, providing the necessary focus and funding to advance its pipeline in autism and neuro-oncology [12]

Core Insights - XTL Biopharmaceuticals is acquiring 85% of NeuroNOS, a subsidiary of Beyond Air, to enhance its position in the autism therapeutics market, which is currently underserved with no FDA-approved disease-modifying therapies available [1][2] - The acquisition is expected to provide XTL with a strong scientific foundation, including leadership from Nobel Laureates and a focus on addressing the underlying biological mechanisms of Autism Spectrum Disorder (ASD) [7][12] Industry Overview - Autism Spectrum Disorder affects approximately 1 in 31 children in the U.S., highlighting a significant public health crisis that has strained healthcare systems and families [3][4] - The U.S. government has recognized the urgency of addressing autism, allocating $50 million in new NIH funding for research initiatives, indicating a shift in regulatory priorities towards autism treatment development [4] Scientific Leadership - NeuroNOS was founded by Professor Haitham Amal, a leading autism researcher, and has recently added two Nobel Laureates, enhancing its scientific credibility and potential for innovation in autism therapeutics [5][7] - The company's research focuses on nitric oxide dysregulation, which has been linked to both autism and brain cancer, establishing a novel therapeutic target [6][8] Technology and Regulatory Status - NeuroNOS's drug development platform utilizes small molecules designed to cross the blood-brain barrier and target nitric oxide abnormalities, aiming to address core pathological mechanisms rather than just symptoms [8] - The company has secured FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma, which provide market exclusivity and expedited regulatory review [9] Transaction Details - The acquisition terms include a 19.9% stake in XTL's post-transaction share capital, $1 million in cash, and milestone payments up to $32.5 million based on clinical and commercial achievements [10][11] - Both XTL and Beyond Air are committed to advancing NeuroNOS's autism treatment programs with urgency [11][12]

Group 1: CFO Transition at Robinhood - Jason Warnick is retiring as CFO of Robinhood, with Shiv Verma stepping into the role, focusing on finance and strategy [2][6] - Warnick emphasizes the importance of capital allocation and influencing the CEO in a CFO's role [3] - Verma has engaged with CEO Vlad Tenev and other leaders to focus on long-term strategic decisions for Robinhood [4] Group 2: CEO-CFO Partnership - The partnership between the CEO and CFO is critical, as CFOs are seen as strategic thought partners amid rapid technological changes [5] - CFOs provide enterprise-wide visibility and help translate ambiguity into actionable decisions [5] Group 3: Robinhood's Performance and Governance - Robinhood experienced significant changes over the past seven years, including workforce reductions and a shift to a general manager model [6] - In 2024, Robinhood reported total net revenue of $2.95 billion and annual net income of $1.41 billion, and joined the S&P 500 in September [6][7] Group 4: Tesla's Q4 2025 Performance - Tesla produced over 434,000 vehicles and delivered over 418,000 vehicles in Q4 2025, with energy storage deployments reaching a record of 14.2 GWh [12] - For the full year 2025, Tesla delivered 1.64 million vehicles, a 9% decrease from 2024, while BYD sold 2.26 million electric vehicles, becoming the largest EV maker [13]

Core Insights - Beyond Air, Inc. has appointed Dan Moorhead as Chief Financial Officer, effective January 5, 2026, succeeding Duke Dewrell, who served as interim CFO since November 2025 [1][2] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide (NO) to enhance patient care, particularly for respiratory illnesses, neurological disorders, and solid tumors [5][6] - The company has received FDA approval and CE Mark for its first system, LungFit PH, aimed at treating term and near-term neonates with hypoxic respiratory failure [5] Leadership Appointment - Dan Moorhead brings over 20 years of finance leadership experience, having previously served as CFO of Zynex, Inc., where he supported significant commercial expansion [3] - Moorhead expressed enthusiasm about joining Beyond Air at a critical time, particularly with the upcoming FDA approval of the second generation LungFit PH and its commercial launch [2][3] Inducement Stock Option - Upon his appointment, Moorhead was granted an inducement stock option for 70,000 shares of the company's common stock, exercisable at the last reported sale price on December 31, 2025 [4] - The stock option has a ten-year term and will vest over four years, with 25% vesting on the first anniversary and the remainder in three equal installments [4] Product Development - Beyond Air is advancing its LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [5][6] - The company is also collaborating with The Hebrew University of Jerusalem on a pre-clinical program for treating autism spectrum disorder and other neurological disorders [6]

Core Insights - Beyond Air, Inc. has expanded its international distribution network for LungFit PH to 39 countries, covering a population of over three billion people [1][2] - The company aims to leverage its unique nitric oxide delivery technology to gain significant market share in key international markets [2] - LungFit PH is designed to generate nitric oxide from ambient air, streamlining hospital operations and reducing environmental impact [3][6] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on using nitric oxide to treat respiratory illnesses, neurological disorders, and solid tumors [4] - The company has received FDA approval and CE Mark for LungFit PH, which is intended for treating neonates with hypoxic respiratory failure [4][8] - Beyond Air is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [4] Product Details - LungFit PH is a cylinder-free, phasic flow generator that can deliver nitric oxide at concentrations ranging from 1 ppm to 80 ppm [6] - The device is compatible with ventilators and aims to replace traditional high-pressure nitric oxide cylinders, offering operational benefits such as reduced inventory and improved safety [6][7] - Beyond Air plans to extend the use of LungFit technology for home treatment of chronic lung infections [7] Research and Development - The company has partnered with The Hebrew University of Jerusalem to develop treatments for autism spectrum disorder and other neurological conditions [5] - Beyond Cancer, Ltd., an affiliate of Beyond Air, is exploring high concentrations of nitric oxide for targeting solid tumors in pre-clinical studies [5]

As filed with the Securities and Exchange Commission on December 11, 2025 Registration No. 333-291699 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Beyond Air, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 47-3812456 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Numbe ...

Company Overview - DoorDash was founded in 2013 by Tony Xu and three fellow Stanford students and has become the clear market leader in the U.S. restaurant delivery sector, controlling approximately 60% of the market, which is more than double that of its closest competitor, Uber Eats [1][2]. Business Strategy - The company is expanding into new retail categories and geographies, utilizing in-house mapping technology to optimize delivery logistics, which provides a competitive edge in the delivery-app market [3]. - DoorDash aims to build a comprehensive catalog of the physical world, leveraging data that is not available on platforms like Google Maps or ChatGPT [4]. Leadership and Innovation - Tony Xu's leadership style is gaining attention from peers in the tech industry, including Meta CEO Mark Zuckerberg, highlighting his influence and strategic vision [4]. - The company has developed a highly efficient logistics engine powered by machine learning, which has been in place for the past decade [6]. AI and Data Utilization - DoorDash is strategically positioned to maintain its dominance in the AI-driven local commerce sector, supported by a vast proprietary dataset and a robust AI infrastructure designed for rapid iteration [7]. - The company integrates AI across all operations, enhancing its service delivery and operational efficiency [7]. Financial Performance - DoorDash has seen significant growth, ranking No. 394 on the Fortune 500 list, having debuted at No. 443 in 2024 [6].